play_arrow

keyboard_arrow_right

skip_previous play_arrow skip_next
00:00 00:00
playlist_play chevron_left
chevron_left
  • cover play_arrow

    Rother Radio (128k) Love Local, Love Music!

  • cover play_arrow

    Rother Radio (64K) Love Local, Love Music!

  • cover play_arrow

    Hit Music Radio (128K) More Music Variety!

  • cover play_arrow

    Hit Music Radio (64K) The Best Variety of Hits!

Business News

Oxford jab scientist set for £20m windfall in ‘New York flotation’

today08/04/2021

Background
share close

The scientist who led the development of the Oxford University-AstraZeneca coronavirus vaccine is on course for a payday of more than £20m through a stock market listing, according to reports.

Professor Sarah Gilbert owns just over 5% of a company she co-founded in 2016 called Vaccitech.

According to the Financial Times, the biotechnology start-up has confidentially filed for an initial public offering in the US – a flotation that could earn her £22m under its last funding round valuation of £425m.

The Oxford/AstraZeneca coronavirus vaccine
Image: The Oxford/AstraZeneca coronavirus vaccine

Vaccitech owns the technology behind the COVID-19 jab – which is being sold by the pharma firm on a not-for-profit basis during the pandemic – and other medical treatments and products.

It was said to be planning a listing on the Nasdaq exchange within weeks as US stock markets hit record levels on the back of expectations of a vaccine-led recovery for the economy.

The Oxford-Astra jab, while hailed as a first rate product, has hit bumps in the road over concerns about a possible link to blood clots in a small number of recipients.

Vaccitech’s shareholders include Professor Gilbert’s Oxford colleague, Professor Adrian Hill, the other co-founder who also has a stake of 5.2%.

More from Business

GV, the venture capital fund of Google’s parent firm Alphabet, has an interest of 12%.

The FT reported that the UK government also owned a stake though any interest was not listed in details lodged with Companies House.

The Nasdaq MarketSite is in Times Square, New York
Image: The Nasdaq has reportedly been chosen for the flotation

Sky News has contacted the Treasury for comment.

Vaccitech is yet to comment.

Any Nasdaq listing would represent a snub to the chancellor’s efforts to make London more attractive for such listings.

Last month, another UK company Cazoo chose to merge with a so-called US-based special purpose acquisition company – or SPAC – backed by billionaire investor Dan Och.

Neil Wilson, chief market analyst at Markets.com, told Sky News: “It’s a bit of a blow to London’s ambitions to become a hub for new listings in areas like life sciences and technology.

“It’s not massive – valued at about $450m I think – but nonetheless a knock to London’s attempt to attract these types of companies, which are going to be the internet giants of the coming decades in my view.

“Coming off the back of the Deliveroo flop, a lot of attention is on the London market and the ability to handle big floats in the broader tech arena.

“The good news is that Oxford Nanopore did choose London for its much larger listing, which is a significant vote of confidence. The Nasdaq has always been the choice for biotech so this really is a big win.”

 Sky News

© Sky News 2021

Written by: Rother Radio News


Previous post

Music News

Liam Payne wishes he’d been less ‘serious’ in One Direction

Liam Payne wishes he'd had "more fun" in One Direction. The 26-year-old singer thinks he was too "serious" when the group were put together in 2020, which earned him the nickname 'Daddy Directioner' and he felt he was given a "different job" to his bandmates because it was felt he could handle the responsibility so he feels like he missed out at the time. Asked what he'd advise his pre-fame […]

today08/04/2021


Similar posts


Search Rother Radio

About Us

Rother Radio – Love Local, Love Music! → Discover more